Last $18.50 USD
Change Today -0.41 / -2.17%
Volume 330.3K
TRNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

tornier nv (TRNX) Snapshot

Open
$18.93
Previous Close
$18.91
Day High
$18.98
Day Low
$18.04
52 Week High
10/25/13 - $21.87
52 Week Low
11/6/13 - $15.17
Market Cap
897.6M
Average Volume 10 Days
282.7K
EPS TTM
$-0.54
Shares Outstanding
48.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TORNIER NV (TRNX)

tornier nv (TRNX) Related Bloomberg News

View More Bloomberg News

tornier nv (TRNX) Related Businessweek News

No Related Businessweek News Found

tornier nv (TRNX) Details

Tornier N.V., a medical device company, designs, manufactures, markets, and sells orthopedic products. It offers a portfolio of approximately 95 products, including joint replacement, trauma, sports medicine, and biologic products to treat extremity joints. The company also provides joint replacement products for hip and knee. It principally serves surgeons who treat musculoskeletal injuries; and disorders of the shoulder, elbow, hand, wrist, ankle, and foot. The company distributes and sells its products through approximately 145 direct sales representatives and 40 independent sales agencies in the United States; and 13 direct sales offices and 25 distributors in approximately 45 countries worldwide. Tornier N.V. is headquartered in Amsterdam, the Netherlands.

1,076 Employees
Last Reported Date: 02/21/14

tornier nv (TRNX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $444.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $354.4K
Senior Vice President of International Commer...
Total Annual Compensation: $366.3K
Senior Vice President of U.S. Commercial Oper...
Total Annual Compensation: $358.8K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $285.7K
Compensation as of Fiscal Year 2013.

tornier nv (TRNX) Key Developments

Tornier N.V. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 29, 2013; Announces Impairment Charges for the Fourth Quarter Ended December 29, 2013; Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2014

Tornier N.V. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 29, 2013. For the quarter, the company reported revenue of $83,392,000 against $79,033,000 a year ago. Operating loss was $7,340,000 against $13,965,000 a year ago. Loss before income taxes was $9,755,000 against $17,043,000 a year ago. Consolidated net loss was $10,699,000 against $4,803,000 a year ago. Basic and diluted loss per share was $0.22 against $0.12 a year ago. Net cash provided by operating activities was $6,661,000 against $3,295,000 a year ago. Purchases of property, plant and equipment was $3,307,000 against $3,405,000 a year ago. Non-GAAP EBITDA was $1,446,000 against non-GAAP LBITDA of $5,940,000 a year ago. Non-GAAP adjusted EBITDA was $9,163,000 against $10,961,000 a year ago. Non-GAAP adjusted net loss was $8,219,000 against $739,000 a year ago. Non-GAAP adjusted net loss per share basic and diluted was $0.17 against $0.02 a year ago. Non-GAAP adjusted free cash flow was $3,886,000 against $12,000 a year ago. For the year, the company reported revenue of $310,959,000 against $277,520,000 a year ago. Operating loss was $24,074,000 against $28,334,000 a year ago. Loss before income taxes was $34,077,000 against $32,679,000 a year ago. Consolidated net loss was $36,426,000 against $21,744,000 a year ago. Basic and diluted loss per share was $0.79 against $0.54 a year ago. Net cash provided by operating activities was $24,982,000 against $14,431,000 a year ago. Purchases of property, plant and equipment was $10,825,000 against $11,291,000 a year ago. Non-GAAP EBITDA was $9,500,000 against $948,000 a year ago. Non-GAAP adjusted EBITDA was $30,438,000 against $32,926,000 a year ago. Non-GAAP adjusted net loss was $27,236,000 against $8,208,000 a year ago. Non-GAAP adjusted net loss per share basic and diluted was $0.59 against $0.20 a year ago. Non-GAAP adjusted free cash flow was $9,648,000 against $1,051,000 a year ago. For the fourth quarter, the company announced impairment of fixed assets of $140,000 against $1,013,000 a year ago. For the first quarter ended March 30, 2014, the company expected revenues to be in the range of $78.5 million to $82.5 million, based on recent currency exchange rates and constant currency revenue to be in the range of $78 million to $82 million. Adjusted EBITDA expected to be in the range of $4.0 million to $6.0 million, or 5.1% to 7.3% of reported revenue. Depreciation and amortization expense expected to be in the range of $10.4 million to $9.8 million. For the fiscal year 2014, the company projected constant currency revenue to be in the range of $302 to $317 million, representing a change in constant currency. Based on recent currency exchange rates, revenue is projected to be in the range of $304.2 to $319.1 million. Adjusted EBITDA expected to be in the range of $22.5 to $27.5 million, or 7.4% to 8.6%. Depreciation and amortization expense expected to be in the range of $45 million to $42 million. Interest expense for fiscal 2014 expected to be in the range of $6.4 million to $7.4 million, including anticipated interest accretion charges of $2.1 million to $2.6 million, relating to contingent consideration payments for the OrthoHelix and certain distributor acquisitions.

Tornier N.V. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 08:30 AM

Tornier N.V. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 08:30 AM. Venue: New York Palace Hotel, New York, New York, United States. Speakers: David H. Mowry, Chief Executive Officer, President and Executive Director, Shawn T. McCormick, Chief Financial Officer and Principal Accounting Officer.

Tornier N.V. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2013

Tornier N.V. provided revenue guidance for the fourth quarter and full year of 2013. For the quarter, the company expects revenue to be in the range of $83 to $84 million. For the full year, the company expects revenue to be in the range of $310.5 to $311.5 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRNX:US $18.50 USD -0.41

TRNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $62.02 USD -0.23
Exactech Inc $22.78 USD -0.32
ICU Medical Inc $56.95 USD -0.20
Merit Medical Systems Inc $13.48 USD -0.08
Wright Medical Group Inc $27.80 USD -0.87
View Industry Companies
 

Industry Analysis

TRNX

Industry Average

Valuation TRNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TORNIER NV, please visit www.tornier.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.